Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis

Arbab Jafari, P. and Ayatollahi, H. and Sadeghi, R. and Sheikhi, M. and Asghari, A. (2018) Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis. Hematology, 23 (10). pp. 778-784.

[img] Text
Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia a meta-analysis.pdf

Download (1MB)

Abstract

Objective: Serine/arginine-rich splicing factor 2 (SRSF2) mutations were detected frequently in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) patients. However, its prognostic value has not yet been fully clarified. Methods: In this meta-analysis, Hazard Ratio (HR) and 95 confidence interval (CI) for overall-survival (OS) were chosen to evaluate the prognostic impact of SRSF2 mutations and to compare SRSF2 mutations to those with wild-type. Results: A total of 2056 patients from 12 studies were obtained. The pooled HRs for OSsuggested that patients with MDS had a poorer prognosis (HR = 1.780, 95 CI (1.410–2.249)), while analysis on SRSF2 mutations revealed no significant effect on the prognosis of CMML patients (HR = 1.091, 95 CI (0.925–1.286)). The frequency of SRSF2 mutations was found to be 11.5 and 39.8 in patients with MDS and CMML, respectively. Discussion: This meta-analysis suggests that SRSF2 has a poor prognosis in patients with MDS, but no prognosis impact on patients with CMML. Conclusion: In conclusion, SRSF2 mutations were significantly related to the shorter OS in patients with MDS which may consider as an adverse prognostic risk factor. Whereas, analysis did not show any prognostic effect on OS of CMML patients with SRSF2 mutations. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.

Item Type: Article
Additional Information: Cited By :7 Export Date: 16 February 2020 CODEN: HMATF Correspondence Address: Arbab Jafari, P.; Department of Hematology and Blood Banking, Faculty of Medicine, Mashhad University of Medical SciencesIran; email: jafariarbab@gmail.com
Uncontrolled Keywords: meta-analysis Myelodysplastic syndrome prognosis SRSF2 mutation Article chronic myelomonocytic leukemia confidence interval diagnostic value gene mutation hazard ratio human meta analysis Newcastle-Ottawa scale overall survival priority journal quality control risk factor SRSF2 gene tumor gene chronic myeloid leukemia disease free survival female genetics male mortality mutation survival rate serine arginine rich splicing factor SRSF2 protein, human Disease-Free Survival Humans Leukemia, Myelogenous, Chronic, BCR-ABL Positive Myelodysplastic Syndromes Serine-Arginine Splicing Factors
Subjects: WH Hemic and Lymphatic System
Divisions: Mashhad University of Medical Sciences
Depositing User: lib2 lib2 lib2
Date Deposited: 08 Jun 2020 08:19
Last Modified: 08 Jun 2020 08:19
URI: http://eprints.mums.ac.ir/id/eprint/17199

Actions (login required)

View Item View Item